Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

Simple item page
dc.contributor.authorBazzino, O
dc.contributor.authorBarrero, C
dc.contributor.authorGarre, L
dc.contributor.authorSosa, A
dc.contributor.authorAylward, P
dc.contributor.authorSlany, J
dc.contributor.authorBeaudry, P
dc.contributor.authorBédard, J
dc.contributor.authorDeLarochellière, R
dc.contributor.authorNguyen, M
dc.contributor.authorBogaty, P
dc.contributor.authorBoudreault, JR
dc.contributor.authorDiodati, JG
dc.contributor.authorDupuis, J
dc.contributor.authorFitchett, D
dc.contributor.authorFung, A
dc.contributor.authorGervais, P
dc.contributor.authorGossard, D
dc.contributor.authorGrandmont, D
dc.contributor.authorHuynh, T
dc.contributor.authorKouz, S
dc.contributor.authorLanger, A
dc.contributor.authorLaramée, P
dc.contributor.authorLemay, M
dc.contributor.authorMaillette, S
dc.contributor.authorMaranda, C
dc.contributor.authorNasmith, J
dc.contributor.authorPesant, Y
dc.contributor.authorPhanuef, D
dc.contributor.authorProulx, G
dc.contributor.authorRuel, M
dc.contributor.authorThompson, C
dc.contributor.authorCorbalan, R
dc.contributor.authorBotero, R
dc.contributor.authorHusted, S
dc.contributor.authorHeikkila, J
dc.contributor.authorCharbonnier, B
dc.contributor.authorMoguel, R
dc.contributor.authorCommerford, P
dc.contributor.authorLandless, P
dc.contributor.authorWeich, D
dc.contributor.authorMaritz, F
dc.contributor.authorMarx, J
dc.contributor.authorFernandes, F
dc.contributor.authorLidón, R
dc.contributor.authorSanz, G
dc.contributor.authorBosch, X
dc.contributor.authorMoccetti, T
dc.contributor.authorAli, N
dc.contributor.authorAnderson, HV
dc.contributor.authorBajwa, T
dc.contributor.authorBorzak, S
dc.contributor.authorBoyek, T
dc.contributor.authorBrewer, D
dc.contributor.authorCambier, P
dc.contributor.authorChivukula, S
dc.contributor.authorCorder, C
dc.contributor.authorEzekowitz, M
dc.contributor.authorFeldman, R
dc.contributor.authorGlickman, L
dc.contributor.authorJang, IK
dc.contributor.authorKlein, M
dc.contributor.authorKorn, D
dc.contributor.authorKraus, S
dc.contributor.authorKwan, T
dc.contributor.authorMann, JT
dc.contributor.authorMarshall, J
dc.contributor.authorMartin, J
dc.contributor.authorMonrad, ES
dc.contributor.authorMueller, H
dc.contributor.authorPenny, W
dc.contributor.authorSchmedtje, J
dc.contributor.authorStrony, J
dc.contributor.authorArmstrong, P
dc.contributor.authorDeCani, J
dc.contributor.authorHirsh, J
dc.contributor.authorPepine, C
dc.contributor.authorRyan, TJ
dc.contributor.authorThéroux, P
dc.contributor.authorCatella-Lawson, F
dc.contributor.authorDiodati, J
dc.contributor.authorRoy, L
dc.contributor.authorWillerson, JT
dc.contributor.authorYusuf, S
dc.contributor.authorZhao, X
dc.contributor.authorSax, FL
dc.contributor.authorHarris, KH
dc.contributor.authorPelletier, G
dc.contributor.authorDavies, R
dc.contributor.authorFlather, M
dc.contributor.authorGosselin, G
dc.contributor.authorHerrmann, H
dc.contributor.authorKells, C
dc.contributor.authorKnudtson, M
dc.contributor.authorThadani, U
dc.contributor.authorSnapinn, SM
dc.contributor.authorGhannam, A
dc.contributor.authorHaggert, B
dc.contributor.authorWatson, A
dc.contributor.authorLis, J
dc.contributor.authorBrancato, C
dc.contributor.authorFong, D
dc.date.accessioned2025-01-21T01:32:42Z
dc.date.available2025-01-21T01:32:42Z
dc.date.issued1998
dc.description.abstractBackground Antithrombotic therapy improves the prognosis of patients with acute coronary syndromes, yet the syndromes remain a therapeutic challenge. We evaluated tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, in the treatment of unstable angina and non-Q-wave myocardial infarction.
dc.description.abstractMethods A total of 1915 patients were randomly assigned in a double-blind manner to receive tirofiban, heparin, or tirofiban plus heparin. Patients received aspirin if its use was not contraindicated. The study drugs were infused for a mean (+/-SD) of 71.3+/-20 hours, during which time coronary angiography and angioplasty were performed when indicated after 48 hours. The composite primary end point consisted of death, myocardial infarction, or refractory ischemia within seven days after randomization.
dc.description.abstractResults The study was stopped prematurely for the group receiving tirofiban alone because of excess mortality at seven days (4.6 percent, as compared with 1.1 percent for the patients treated with heparin alone). The frequency of the composite primary end point at seven days was lower among the patients who received tirofiban plus heparin than among those who received heparin alone (12.9 percent vs, 17.9 percent; risk ratio, 0.68; 95 percent confidence interval, 0.53 to 0.88; P=0.004). The rates of the composite end point in the tirofiban-plus-heparin group were also lower than those in the heparin-only group at 30 days (18.5 percent vs. 22.3 percent, P=0.03) and at 6 months (27.7 percent vs, 32.1 percent, P=0.02). At seven days, the frequency of death or myocardial infarction was 4.9 percent in the tirofiban-plus-heparin group, as compared with 8.3 percent in the heparin-only group (P=0.006). The comparable figures at 30 days were 8.7 percent and 11.9 percent (P=0.03), respectively, and those at 6 months were 12.3 percent and 15.3 percent (P=0.06). The benefit was consistent in the various subgroups of patients and in those treated medically as well as those treated with angioplasty. Major bleeding occurred in 3.0 percent of the patients receiving heparin alone and 4.0 percent of the patients receiving combination therapy (P=0.34).
dc.description.abstractConclusions When administered with heparin and aspirin, the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban was associated with a lower incidence of ischemic events in patients with acute coronary syndromes than in patients who received only heparin and aspirin. (C) 1998, Massachusetts Medical Society.
dc.fuente.origenWOS
dc.identifier.issn0028-4793
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/97306
dc.identifier.wosidWOS:000073699100002
dc.issue.numero21
dc.language.isoen
dc.pagina.final1497
dc.pagina.inicio1488
dc.revistaNew england journal of medicine
dc.rightsacceso restringido
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleInhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
dc.typeartículo
dc.volumen338
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas